Table 4.
Effect of living distance on the phase I and II IgG antibody titres
| Living distance from infected farm in meters, within case-control study † | phase I IgG <1:1,024 / ≥1:1,024 | phase II IgG <1:1,024 / ≥1:1,024 | ||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| >5,000 | ref* | ref* | ref* | ref* |
| >2,000 - 5,000 | 0.42 (0.16 - 1.11) | 0.079 | 0.59 (0.23 - 1.51) | 0.274 |
| 0 - 2,000 | 0.67 (0.33 - 1.36) | 0.264 | 1.00 (0.46- 2.18) | 0.992 |
| Living distance from infected farm in meters, within Q-HORT study ¥ | phase I IgG <1:1,024 / ≥1:1,024 | phase II IgG <1:1,024 / ≥1:1,024 | ||
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| >5,000 | ref* | ref* | ref* | ref* |
| >2,000 - 5,000 | 0.52 (0.28 - 0.93) | 0.029 | 0.98 (0.76 - 1.25) | 0.843 |
| 0 - 2,000 | 0.65 (0.41 - 1.03) | 0.066 | 0.98 (0.79 - 1.22) | 0.857 |
*ref = reference category.
†Case-control study exists of acute and possible chronic Q fever patients from the Jeroen Bosch Hospital, Bernhoven Hospital and Laboratory for Pathology and Medical Microbiology.
¥Q-HORT study exists of acute Q fever, possible, probable and proven chronic Q patients from the Jeroen Bosch Hospital, Bernhoven Hospital and Laboratory for Pathology and Medical Microbiology.